CarThera
Carthera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat severe brain disorders, including glioblastoma and other CNS diseases. Their mission is to revolutionize brain treatments by overcoming the blood-brain barrier and enabling targeted drug delivery.
Industries
Nr. of Employees
small (1-50)
Patents
Method and system for detecting a fault in acoustic coupling between an ultrasonic device and a tissue to be treated
US-12246194-B2
View DetailsImplantable ultrasound generating treating device for brain treatment, apparatus comprising such device and method implementing such device
US-11738214-B2
View Details
Method and system for detecting a fault in acoustic coupling between an ultrasonic device and a tissue to be treated
US-12246194-B2
View DetailsImplantable ultrasound generating treating device for brain treatment, apparatus comprising such device and method implementing such device
US-11738214-B2
View DetailsProducts
Implantable ultrasound system for transient blood–brain barrier opening
An intracranial, multi-emitter implantable ultrasound system that delivers low-intensity pulsed ultrasound sonications to produce short-duration, reversible BBB opening to enhance local delivery of therapeutic agents.
Implantable ultrasound system for transient blood–brain barrier opening
An intracranial, multi-emitter implantable ultrasound system that delivers low-intensity pulsed ultrasound sonications to produce short-duration, reversible BBB opening to enhance local delivery of therapeutic agents.
Services
Collaborative planning and execution of investigator-led and multicenter clinical trials evaluating implantable ultrasound-mediated BBB opening combined with systemic therapies.
Joint preclinical programs to evaluate BBB opening, drug distribution, safety and combinatory therapeutic efficacy using animal models and analytical endpoints.
Collaborative planning and execution of investigator-led and multicenter clinical trials evaluating implantable ultrasound-mediated BBB opening combined with systemic therapies.
Joint preclinical programs to evaluate BBB opening, drug distribution, safety and combinatory therapeutic efficacy using animal models and analytical endpoints.
Expertise Areas
- Blood–brain barrier disruption for therapeutic delivery
- Implantable ultrasound therapeutics for CNS
- Clinical trial management for CNS medical devices
- Translational oncology focused on glioblastoma and brain metastases
Key Technologies
- Low-intensity pulsed ultrasound (LIPU)
- Implantable intracranial ultrasound transducers
- Microbubble-mediated ultrasound contrast agents
- MRI-based monitoring and quantification